In yesterday’s Wall Street session, Adaptive Biotechnologies Corp (NASDAQ:ADPT) shares traded at $6.39, up 1.11% from the previous session.
ADPT stock price is now 15.37% away from the 50-day moving average and 50.54% away from the 200-day moving average. The market capitalization of the company currently stands at $957.79M.
On January 05, 2023, Scotiabank recently initiated its ‘Sector Outperform’ rating on the stock quoting a target price of $15, while ‘Piper Sandler’ rates the stock as ‘Overweight’
In other news, PISKEL KYLE, Chief Financial Officer sold 248 shares of the company’s stock on Nov 18 ’24. The stock was sold for $1,235 at an average price of $4.98. Upon completion of the transaction, the Chief Financial Officer now directly owns 154,330 shares in the company, valued at $0.99 million. An SEC document containing details of the transaction can be found on the SEC’s website. On Aug 22 ’24, SVP and General Counsel Taylor Stacy L sold 26,922 shares of the business’s stock. A total of $121,079 was realized by selling the stock at an average price of $4.50. This leaves the insider owning 139,365 shares of the company worth $0.89 million. A total of 3.28% of the company’s stock is owned by insiders.
During the past 12 months, Adaptive Biotechnologies Corp has had a low of $2.28 and a high of $7.07. As of last week, the company has a debt-to-equity ratio of 1.00, a current ratio of 3.52, and a quick ratio of 3.38. The fifty day moving average price for ADPT is $5.5078 and a two-hundred day moving average price translates $4.231175 for the stock.
The latest earnings results from Adaptive Biotechnologies Corp (NASDAQ: ADPT) was released for 2024-09-30. The net profit margin was -110.13% and return on equity was -66.69% for ADPT. The company reported revenue of $46.44 million for the quarter, compared to $37.92 million a year earlier. Comparatively to last year’s same quarter, the company’s quarterly revenue rose 22.46 percent.
